Premium
Flow cytometry “Ogata score” for the diagnosis of myelodysplastic syndromes in a real‐life setting. A Latin American experience
Author(s) -
Grille Montauban Sofía,
HernandezPerez Carlos R.,
Velloso Elvira D. R. P.,
Novoa Viviana,
LorandMetze Irene,
Gonzalez Jaqueline,
Solari Liliana,
Cismondi Valeria,
Serrano Juan Carlos,
Burgnini Andreína,
RabeloCarrasco Laura J.,
Bacal Nydia,
Trias Natalia,
Guevara Romina,
Rico Vido Joyce,
Crisp Renee,
Enrico Alicia,
Boada Matilde,
Pereira Cunha Fernanda G.,
Fanessi Viviana,
Venegas María Belén,
Issouribehere Diego,
Novoa Andrea,
Lens Daniela
Publication year - 2019
Publication title -
international journal of laboratory hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.705
H-Index - 55
eISSN - 1751-553X
pISSN - 1751-5521
DOI - 10.1111/ijlh.13047
Subject(s) - myelodysplastic syndromes , medicine , flow cytometry , intensive care medicine , immunology , bone marrow
Flow cytometry (FC) is a helpful tool for the diagnosis of myelodysplastic syndrome (MDS). Different FC score systems have been developed. The “Ogata score” is a simple diagnostic score that has been validated having a sensitivity of 69% and a specificity of 92% in low‐risk MDS. We aimed to study the feasibility and the utility of the “Ogata score” for the diagnosis of MDS among Latin America (LA) Laboratories. Methods This is a case and control study conducted in LA institutions members of Grupo Latinoamericano de Mielodisplasia (GLAM). A total of 146 MDS patients and 57 control patients were included. “Ogata score” was calculated. Results The sensitivity of “Ogata score” was 75.6% (95% CI, 66.8‐81.3), specificity was 91.2% (95% CI, 79.7‐96.7), PPV was 95.6% (95% CI, 88.5‐98.3), and NPV was 65.4% (95% CI, 49.1‐71.9). In low/intermediate‐1 IPSS patients group, the sensitivity was 70.1% (95% CI, 60.2‐78.2), specificity was 91.2% (CI‐95%, 79.7‐96.7), PPV was 94.2% (95% CI, 86.4‐97.8), and NPV was 62.1% (95% CI, 53.0‐78.7). In the group of patients “without MDS specific markers” (patients without ring sideroblasts, blast excess, or chromosomal abnormalities), the sensitivity was 66.7% (CI‐95%, 55.8‐76.0), specificity was 91.2% (95% CI, 79.7‐96.7), PPV was 92.3% (95% CI, 82.2‐97.1), and NPV was 63.5% (95% CI, 51.9‐73.5). Conclusions The diagnostic power found in this study was similar to the reported by Della‐Porta et al. Also in LA, the analysis was made in modern equipment with acquisition of at least 100 000 events which permits a good reproducibility of the results.